Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Reviva Pharmaceuticals Holdings, Inc. RVPH

Healthcare Biotechnology
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system and respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug... see more

Recent & Breaking News (NDAQ:RVPH)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

Accesswire May 4, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

Newsfile April 30, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

PR Newswire April 28, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

Accesswire April 26, 2024

RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH

Business Wire April 25, 2024

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

GlobeNewswire April 15, 2024

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire April 15, 2024

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

GlobeNewswire March 28, 2024

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

GlobeNewswire March 26, 2024

Reviva to Present at the UBS Virtual CNS Day

GlobeNewswire March 11, 2024

Reviva to Present at the 36th Annual ROTH Conference

GlobeNewswire March 7, 2024

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire February 20, 2024

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

GlobeNewswire February 6, 2024

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

GlobeNewswire January 25, 2024

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Accesswire January 10, 2024

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

GlobeNewswire January 4, 2024

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

GlobeNewswire December 11, 2023

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

GlobeNewswire November 30, 2023

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire November 20, 2023

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire November 16, 2023